益佰制药(600594) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter was CNY 824,625,331.83, a decline of 14.44% year-on-year[6] - Net profit attributable to shareholders decreased by 41.54% to CNY 59,230,798.23 compared to the same period last year[6] - Basic and diluted earnings per share fell by 41.41% to CNY 0.075[6] - Net profit for Q1 2019 was ¥54,080,240.43, a decline of 49.1% from ¥106,282,091.77 in Q1 2018[33] - Operating profit for Q1 2019 was ¥78,394,468.72, down 35.7% from ¥122,158,737.49 in Q1 2018[33] - The company reported a total comprehensive income of ¥54,080,240.43 for Q1 2019, a decrease of 49.1% compared to ¥106,282,091.77 in Q1 2018[33] - The company's total revenue for Q1 2019 was CNY 340.60 million, a decrease of 23.2% compared to CNY 443.17 million in Q1 2018[35] - Net profit for Q1 2019 was CNY 51.17 million, representing a significant increase of 102.5% from CNY 25.26 million in Q1 2018[35] - The total comprehensive income for Q1 2019 was CNY 51.17 million, compared to CNY 25.26 million in Q1 2018, indicating overall growth[36] Cash Flow and Investments - The net cash flow from operating activities improved to CNY 164,776,410.90, compared to a negative cash flow of CNY -154,209,766.34 in the previous year[6] - The company reported a net cash flow from investing activities of CNY 383,402,800.26 in Q1 2019, a significant recovery from CNY -109,826,519.96 in Q1 2018, mainly due to the receipt of equity transfer payments[17] - The company reported cash inflows from investment activities of CNY 414.53 million, with a net cash flow from investment activities of CNY 383.40 million[39] - In Q1 2019, the company reported a net cash flow from operating activities of CNY 108,025,688.15, a significant improvement compared to a net outflow of CNY 167,399,476.33 in Q1 2018[40] - Cash inflows from financing activities decreased to CNY 190,547,380.00 in Q1 2019 from CNY 316,900,000.00 in Q1 2018, reflecting reduced borrowing[41] Assets and Liabilities - Total assets decreased by 11.63% to CNY 5,722,586,941.32 compared to the end of the previous year[6] - As of March 31, 2019, the total assets amounted to CNY 5,722,586,941.32, a decrease from CNY 6,475,568,370.27 as of December 31, 2018, reflecting a decline of approximately 11.7%[24] - The total current assets decreased to CNY 2,602,913,137.20 from CNY 3,120,998,804.50, representing a reduction of about 16.5%[24] - Total liabilities decreased to CNY 2,006,306,232.00 from CNY 2,517,632,614.13, representing a decrease of approximately 20.2%[26] - The company's total assets were reported at CNY 6,475,568,370.27, with current assets totaling CNY 2,309,052,842.19 and non-current assets at CNY 2,962,097,065.11[46] Equity and Shareholder Information - Net profit attributable to shareholders decreased by 41.54% to CNY 59,230,798.23 compared to the same period last year[6] - The equity attributable to shareholders increased to CNY 3,562,671,602.65 from CNY 3,503,440,804.42, showing a growth of about 1.7%[26] - The company's equity increased to ¥2,938,290,553.27 in Q1 2019, compared to ¥2,887,117,706.02 in Q1 2018, showing a growth of 1.8%[31] Research and Development - R&D expenses increased by 74.34% to CNY 19,901,601.62 in Q1 2019 from CNY 11,415,576.32 in Q1 2018, reflecting increased investment in R&D projects[15] - The company's R&D expenses increased to ¥19,901,601.62 in Q1 2019, up 74.5% from ¥11,415,576.32 in Q1 2018[32] - Research and development expenses increased to CNY 13.33 million, up from CNY 5.82 million in the previous year, indicating a focus on innovation[35] Financial Management - Financial expenses decreased by 97.17% to CNY 612,384.28 in Q1 2019 from CNY 21,602,721.12 in Q1 2018, primarily due to the reclassification of government subsidies[15] - The company incurred financial expenses of CNY 425.37 thousand, significantly lower than CNY 20.50 million in Q1 2018, reflecting improved financial management[35]